A role for 5-HT


Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
12 2020
Historique:
pubmed: 17 10 2019
medline: 7 9 2021
entrez: 17 10 2019
Statut: ppublish

Résumé

5-HT4 receptor stimulation has pro-cognitive and antidepressant-like effects in animal experimental studies; however, this pharmacological approach has not yet been tested in humans. Here we used the 5-HT4 receptor partial agonist prucalopride to assess the translatability of these effects and characterise, for the first time, the consequences of 5-HT4 receptor activation on human cognition and emotion. Forty one healthy volunteers were randomised, double-blind, to a single dose of prucalopride (1 mg) or placebo in a parallel group design. They completed a battery of cognitive tests measuring learning and memory, emotional processing and reward sensitivity. Prucalopride increased recall of words in a verbal learning task, increased the accuracy of recall and recognition of words in an incidental emotional memory task and increased the probability of choosing a symbol associated with a high likelihood of reward or absence of loss in a probabilistic instrumental learning task. Thus acute prucalopride produced pro-cognitive effects in healthy volunteers across three separate tasks. These findings are a translation of the memory enhancing effects of 5-HT4 receptor agonism seen in animal studies, and lend weight to the idea that the 5-HT4 receptor could be an innovative target for the treatment of cognitive deficits associated with depression and other neuropsychiatric disorders. Contrary to the effects reported in animal models, prucalopride did not reveal an antidepressant profile in human measures of emotional processing.

Sections du résumé

BACKGROUND
5-HT4 receptor stimulation has pro-cognitive and antidepressant-like effects in animal experimental studies; however, this pharmacological approach has not yet been tested in humans. Here we used the 5-HT4 receptor partial agonist prucalopride to assess the translatability of these effects and characterise, for the first time, the consequences of 5-HT4 receptor activation on human cognition and emotion.
METHODS
Forty one healthy volunteers were randomised, double-blind, to a single dose of prucalopride (1 mg) or placebo in a parallel group design. They completed a battery of cognitive tests measuring learning and memory, emotional processing and reward sensitivity.
RESULTS
Prucalopride increased recall of words in a verbal learning task, increased the accuracy of recall and recognition of words in an incidental emotional memory task and increased the probability of choosing a symbol associated with a high likelihood of reward or absence of loss in a probabilistic instrumental learning task. Thus acute prucalopride produced pro-cognitive effects in healthy volunteers across three separate tasks.
CONCLUSIONS
These findings are a translation of the memory enhancing effects of 5-HT4 receptor agonism seen in animal studies, and lend weight to the idea that the 5-HT4 receptor could be an innovative target for the treatment of cognitive deficits associated with depression and other neuropsychiatric disorders. Contrary to the effects reported in animal models, prucalopride did not reveal an antidepressant profile in human measures of emotional processing.

Identifiants

pubmed: 31615585
doi: 10.1017/S0033291719002836
pii: S0033291719002836
doi:

Substances chimiques

Benzofurans 0
Serotonin 5-HT4 Receptor Agonists 0
prucalopride 0A09IUW5TP

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2722-2730

Subventions

Organisme : Medical Research Council
ID : MR/P012604/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S003037/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K022202/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Auteurs

Susannah E Murphy (SE)

University Department of Psychiatry, Warneford Hospital, University of Oxford, OX3 7JX, UK.
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.

Lucy C Wright (LC)

University Department of Psychiatry, Warneford Hospital, University of Oxford, OX3 7JX, UK.
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.

Michael Browning (M)

University Department of Psychiatry, Warneford Hospital, University of Oxford, OX3 7JX, UK.
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.

Philip J Cowen (PJ)

University Department of Psychiatry, Warneford Hospital, University of Oxford, OX3 7JX, UK.
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.

Catherine J Harmer (CJ)

University Department of Psychiatry, Warneford Hospital, University of Oxford, OX3 7JX, UK.
Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH